Study S001259

Therapeutic Targets in African-American Youth With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT02960659
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2017-05-09
Primary completion: 2022-05-20
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions: Type 2 Diabetes
Interventions: DRUG:Liraglutide; DRUG:Metformin
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:17-DK-0013

Registered primary outcomes

Change in Absolute Gluconeogenesis From Baseline to 12 Weeks [Baseline to 12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019860	Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study. Glaros SB, Gut microbes	2025	Randomized trial	PMID 41020378 DOI	cites ClinicalTrials.gov:NCT02960659; registry reference DERIVED:41020378